A number of other hedge funds also recently bought and sold shares of UNH. Capital International Investors boosted its holdings in shares of UnitedHealth Group by 399.3% during the 3rd quarter. Capital International Investors now owns 4,132,602 shares of the healthcare conglomerate’s stock worth $809,370,000 after buying an additional 3,304,902 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of UnitedHealth Group by 146.0% in the 3rd quarter. Jennison Associates LLC now owns 5,541,977 shares of the healthcare conglomerate’s stock worth $1,085,396,000 after purchasing an additional 3,289,470 shares in the last quarter. Egerton Capital UK LLP bought a new position in shares of UnitedHealth Group in the 4th quarter worth $368,905,000. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of UnitedHealth Group by 72.1% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,919,846 shares of the healthcare conglomerate’s stock worth $423,249,000 after purchasing an additional 804,091 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of UnitedHealth Group by 22.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,323,180 shares of the healthcare conglomerate’s stock worth $953,088,000 after purchasing an additional 792,527 shares in the last quarter. 87.30% of the stock is owned by institutional investors and hedge funds.
Guggenheim Capital LLC lessened its holdings in UnitedHealth Group (NYSE:UNH) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 569,742 shares of the healthcare conglomerate’s stock after selling 62,062 shares during the quarter. UnitedHealth Group accounts for approximately 0.3% of Guggenheim Capital LLC’s investment portfolio, making the stock its 21st biggest position. Guggenheim Capital LLC owned about 0.06% of UnitedHealth Group worth $125,605,000 at the end of the most recent quarter.
UNH stock opened at $232.03 on Wednesday. The firm has a market capitalization of $226.72 billion, a PE ratio of 23.04, a price-to-earnings-growth ratio of 1.36 and a beta of 0.75. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.73. UnitedHealth Group has a 1-year low of $166.65 and a 1-year high of $250.79.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 EPS for the quarter, topping analysts’ consensus estimates of $2.91 by $0.13. The business had revenue of $55.19 billion during the quarter, compared to analysts’ expectations of $54.90 billion. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.37 earnings per share. research analysts anticipate that UnitedHealth Group will post 12.61 EPS for the current fiscal year.
In other news, Director Richard T. Burke sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 23rd. The stock was sold at an average price of $234.20, for a total value of $3,513,000.00. Following the completion of the sale, the director now directly owns 1,761,533 shares of the company’s stock, valued at approximately $412,551,028.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry C. Renfro sold 22,184 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $228.94, for a total value of $5,078,804.96. Following the completion of the sale, the insider now directly owns 173,229 shares of the company’s stock, valued at $39,659,047.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,019 shares of company stock valued at $16,550,733. Corporate insiders own 0.87% of the company’s stock.
UNH has been the topic of a number of recent research reports. Zacks Investment Research upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $240.00 target price on the stock in a report on Tuesday, April 3rd. Deutsche Bank increased their price target on UnitedHealth Group to $260.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $235.00 target price on shares of UnitedHealth Group in a research report on Tuesday, January 16th. BMO Capital Markets increased their price target on UnitedHealth Group from $14.50 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 17th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of UnitedHealth Group in a research note on Wednesday, April 18th. Two research analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and a consensus price target of $253.70.
UnitedHealth Group Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.